ClinicalTrials.gg
CompletedNCT00837967Updated Aug 29, 2012Results posted

Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients

A Phase 3 interventional study of Symbicort Turbuhaler and Terbutaline Turbuhaler in Asthma, sponsored by AstraZeneca. Completed at 2 sites in Japan. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-08-29.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
215th of 248
25 · median 175
Started
2009
with 15 others
Phase 3
121 of 359
6 open now
Registered
121st of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 215th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2009, is one of 121 in phase 3, and was the 121st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler® 160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on top of Symbicort® Turbuhaler® 160/4.5 μg 1 inhalation twice a day (bid) in adult asthma patients.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Symbicort Turbuhaler
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures
  • A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition
  • > 70% of predicted normal value pre-bronchodilator

Exclusion criteria

Exclusion Criteria:

  • Having a known or suspected allergy to study therapy (active drugs or additive)
  • Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure
  • Having been treated with oral, parenteral or rectal within 4 weeks, or with depot parenteral glucocorticoids within 3 months
  • Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    First Symbicort, then Terbutaline

    Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days

    Drug: Symbicort Turbuhaler · Drug: Terbutaline Turbuhaler

  • Experimental
    First Turbuhaler, then Symbicort

    Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,

    Drug: Symbicort Turbuhaler · Drug: Terbutaline Turbuhaler

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Total number of adverse events

    Time frame: 3 days

  2. Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)

    The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

    Time frame: up to 740 min after start dosing for each treatment day

  3. Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)

    The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

    Time frame: up to 140 min after start dosing for each treatment day

  4. Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)

    The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

    Time frame: up to 740 min after start dosing for each treatment day

  5. Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)

    The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

    Time frame: up to 740 min after start dosing for each treatment day

  6. Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)

    The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

    Time frame: up to 740 min after start dosing for each treatment day

07

Results

Posted Aug 29, 2012

Participant flow

Patients recruited from 2 hospitals in Japan between January 2009 and July 2009. 28 patients enrolled; 25 patients randomized, 3 patients were not randomized (1 due to incorrect enrollment and 2 due to adverse event)

First Intervention
Participant flow — First Intervention
MilestoneSymbicort First, Then TerbutalineTerbutaline First, Then Symbicort
Started1312
Completed1312
Not completed00
Washout Period of 7 - 14 Days
Participant flow — Washout Period of 7 - 14 Days
MilestoneSymbicort First, Then TerbutalineTerbutaline First, Then Symbicort
Started1312
Completed1112
Not completed20
Withdrew: Adverse event20
Second Intervention
Participant flow — Second Intervention
MilestoneSymbicort First, Then TerbutalineTerbutaline First, Then Symbicort
Started1112
Completed1112
Not completed00

Outcome measures

PrimaryAdverse Events

Total number of adverse events

Time frame:
3 days
Reported as:
Number · adverse events
Adverse Events
adverse eventsSymbicortTerbutaline
Adverse Events1424
PrimarySerum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

Time frame:
up to 740 min after start dosing for each treatment day
Reported as:
Mean · mEq/L
Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)
mEq/LSymbicortTerbutaline
Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)4.01 ± 0.253.88 ± 0.26
PrimaryBlood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

Time frame:
up to 140 min after start dosing for each treatment day
Reported as:
Mean · mg/dLiters
Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)
mg/dLitersSymbicortTerbutaline
Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)121.1 ± 20.3129.5 ± 22.0
PrimaryElectrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)

The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

Time frame:
up to 740 min after start dosing for each treatment day
Reported as:
Mean · ms
Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)
msSymbicortTerbutaline
Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)411.71 ± 15.07414.33 ± 14.04
PrimaryVital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

Time frame:
up to 740 min after start dosing for each treatment day
Reported as:
Mean · mmHg
Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)
mmHgSymbicortTerbutaline
Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)115.3 ± 6.3114.9 ± 8.0
PrimaryVital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)

The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.

Time frame:
up to 740 min after start dosing for each treatment day
Reported as:
Mean · beats/min
Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)
beats/minSymbicortTerbutaline
Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)70.0 ± 6.674.1 ± 7.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort—0/25 (0%)7/25 (28%)
Terbutaline—0/23 (0%)15/23 (65.2%)
Most frequent other events
Most frequent other events
EventSymbicortTerbutaline
TremorNervous system disorders3/254/23
PalpitationsCardiac disorders1/253/23
TachycardiaCardiac disorders1/253/23
Blood Pressure DecreasedInvestigations2/253/23
NasopharyngitisInfections and infestations2/252/23

Baseline characteristics

Age Continuous
Age Continuous(years)All Study Participants
Mean44.3 ± 14.8
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female15
Male10
08

Study locations

2 sites
  • Research Site
    Ibaragi, Japan
  • Research Site
    Tokyo, Japan
09

References and documents

Publications

  • Saito T, Hasunuma T. Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler(R) in Japanese patients with asthma: a randomized, double-blind, crossover, active comparator-controlled, phase III study. Clin Drug Investig. 2012 Jan 1;32(1):51-61. doi: 10.2165/11595440-000000000-00000. PubMed 22024920 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2009
First posted
Feb 6, 2009
Start
Jan 2009
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Aug 29, 2012
Last update
Aug 29, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00837967
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 6, 2009
Start date
Jan 2009
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Aug 29, 2012
Last update
Aug 29, 2012

Study contacts

Tomas Andersson, MD
study director · AstraZeneca R&D Lund

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

Start the discussion